Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study To Evaluate The Safety And Efficacy Of ALX-101 Topical Gel Administered Twice Daily In Adult And Adolescent Subjects With Moderate Atopic Dermatitis

NCT03859986 is registered in ClinicalTrials.gov with Ralexar Therapeutics, Inc. as lead sponsor.

NCT NCT03859986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03859986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study To Evaluate The Safety And Efficacy Of ALX-101 Topical Gel Administered Twice Daily In Adult And Adolescent Subjects With Moderate Atopic Dermatitis
Lead sponsor
Ralexar Therapeutics, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
March 8, 2019
Completion date
January 31, 2020
Enrollment
124 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis eczema